Xoma Halts Development Of Acne Therapy XMP.629, Will Evaluate BPI Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Following disappointing Phase II results, Xoma will not conduct future trials with the bactericidal/permeability-increasing protein derivative XMP.629, its lead candidate. Earlier-stage BPI-derived products are under evaluation.
You may also be interested in...
Xoma’s New Business Strategy Emphasizes Proprietary Pipeline
Antibody developer’s near-term focus is on advancing its anti-inflammatory agent 052 and antimicrobial peptide 629 and partnering Neuprex.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.